-transparent.png){kind=logo}
The dexamethasone suppression test (DST) is being increasingly used in psychiatry, especially in the differential diagnosis of affective disorders. In light of this, the National Institute of Mental Health convened a workshop of clinical scientists drawn from neuroendocrinology, psychopathology, and general clinical psychiatry to review the evidence for the efficacy of the use of the DST in psychiatry. Specifically considered were DST's relevance to differential diagnosis, its use as a predictor of response to treatment, its relationship with other biologic variables, and technical issues. The panelists concluded that at this time there are no clear indications for routine use of the DST in diagnosis or clinical management of depression, although it is a useful research tool. Areas of potential utility include prediction of suicidal activity, prediction of relapse, and differential diagnosis.
R M Hirschfeld, and
S H Koslow, and
D J Kupfer
February 1985,
The Journal of clinical psychiatry,
R M Hirschfeld, and
S H Koslow, and
D J Kupfer
January 1998,
Psychopharmacology bulletin,
R M Hirschfeld, and
S H Koslow, and
D J Kupfer
May 2021,
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists,
R M Hirschfeld, and
S H Koslow, and
D J Kupfer
October 2001,
Psychopharmacology,
R M Hirschfeld, and
S H Koslow, and
D J Kupfer
September 1982,
The West Virginia medical journal,
R M Hirschfeld, and
S H Koslow, and
D J Kupfer
March 1981,
Journal of clinical psychopharmacology,
R M Hirschfeld, and
S H Koslow, and
D J Kupfer
January 1986,
L'union medicale du Canada,
R M Hirschfeld, and
S H Koslow, and
D J Kupfer
January 1987,
Sbornik vedeckych praci Lekarske fakulty Karlovy university v Hradci Kralove,
R M Hirschfeld, and
S H Koslow, and
D J Kupfer
March 1987,
The New Zealand medical journal,
R M Hirschfeld, and
S H Koslow, and
D J Kupfer
October 1984,
The British journal of psychiatry : the journal of mental science,
